Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Consumer Reports Health Questions Use of Statins by Children and Some Women


News provided by

Consumer Reports

Jun 29, 2010, 06:00 ET

Share this article

Share toX

Share this article

Share toX

Analyzes the Effectiveness and Safety of Statin Use for Those Who Need It

Recommendations for Choosing a "Best Buy" Statin and Strategies for Money-Saving

YONKERS, N.Y., June 29 /PRNewswire-USNewswire/ -- A series of new reports from Consumer Reports Best Buy Drugs (BBD) caution that the benefits of statin use by children and some women may not outweigh the risks. Drugs to lower cholesterol - including statins - are the most commonly prescribed drugs in the U.S. and garnered more than $14 billion in sales last year.

The BBD reports also analyze the effectiveness of statin drugs to lower cholesterol, reduce the risk of heart attack and death and to treat people who have cardiovascular disease. The report finds that a number of low-cost generic statins are as effective and safe as more expensive brand-name drugs in reducing these risks. The Consumer Reports BBD reports coincide with the introduction of Livalo, the so-called 7th statin, in an already crowded class of drugs.

The reports, available for free at www.ConsumerReportsenEspanol.org, note that there are no long-term studies of statin use in kids that establish whether or not these medications reduce the number of heart attacks or other cardiovascular events in adulthood. There is also concern over the long-term potential risk for children and adolescents who use these medications for years or decades, particularly the effects on the developing central nervous system, organs, immune function, and hormone levels.  For women who only have high LDL, the bad cholesterol, and no heart disease, the risks of statins might outweigh the benefits. Risks include headache, joint and muscle pain, and diarrhea. Other risks that are rarer include liver damage and rhabdomylosis, a breakdown of muscle tissue that can lead to coma and even death. There is also an association with an increased risk of type 2 diabetes.

"Contrary to what many consumers believe, we don't have solid medical evidence supporting the use of statins in children and there is no long-term safety data tracking kids who take statins for 10 or 20 years.  And when it comes to healthy women, statins limited benefits may not outweigh their risks," said John Santa, M.D., M.P.H., director of the Consumer Reports Health Ratings Center.

Since the first statin, lovastatin, came on the market in 1987, statins have been a boon to the pharmaceutical industry.  Cholesterol-lowering drugs were the most commonly prescribed drugs in the U.S. in 2009 and collectively earned more than $14 billion dollars last year alone, according to IMS Health.  When adults have high levels of low-density lipoprotein (LDL), known as the bad cholesterol, they are at increased risk of heart disease and heart attack.  Statins lower LDL cholesterol levels and can decrease blockages in the arteries that supply the heart, brain and leg muscles in people who have atherosclerosis.  

The Seventh Statin: What It Means for Consumers

The Consumer Reports BBBD reports coincide with the arrival of Livalo, the so called "7th Statin," which industry watchers expect to be promoted as a high potency drug, though it has not earned solid proof of preventing a cardiovascular event.  "With Livalo arriving on market, there's the potential for consumers to hear just one message - save your life, get the hot new statin.   Our concern is that consumers may not need such a high-potency statin, or they may not need one at all.  And if a statin is needed, much more is known about the safety profile and side affects of the older statins," said Santa.  According to a 2009 poll by the Consumer Reports National Research Center, one in five adults have asked a doctor for a drug they saw advertised and the majority of those requests were granted.

For people who do need to take a statin, Consumer Reports Best Buy Drugs recommends the best choices based on a systematic review of the medical evidence, noting that the use of a high potency statin such as Crestor, Lipitor, Livalo, or generic simvastatin, should be reserved for patients who need to reduce their LDL cholesterol by more than 30 percent. Evidence has mounted in recent years that the risk of life-threatening rhabdomyolysis from statins increases with the use of higher doses.

For people who need to lower their LDL by less than 30 percent, Consumer Reports Best Buy Drugs recommends starting with generic lovastatin or pravastatin.  These generics can be purchased for as little as $15 a month versus $125 for a branded drug like Crestor; the savings over a year can add up to as much as $1,300.  Since using a statin drug is considered a lifetime commitment, the savings over several years can amount to virtually thousands, even tens of thousands, of dollars.  Lipitor, the #1 highest selling branded drug in the U.S., costs up to $ 168 a month but is expected to become available as a lower-cost generic in 2011.

Guidance for Parents of Children with Elevated LDL

In a detailed report about kids and statins, Consumer Reports Best Buy Drugs speaks to a growing audience of parents whose children have about a one in five chance of becoming obese and, according to recent estimates by the Centers for Disease Control and Prevention (CDC), the same likelihood of lipid abnormalities.  Consumer Reports BBD suggests the following considerations for parents weighing long-term statin therapy for their children:

  • First, identify whether your child has any of the traditional risk factors for cardiovascular disease: being overweight or obese; having diabetes; having a family history of premature heart disease; or being a smoker.
  • If your child does have one of these risk factors, improve the child's diet and increase physical activity with a goal of weight loss if it is needed.  Lowering your child's cholesterol without a drug is preferable.  
  • For children who have elevated cholesterol but do not have traditional risk factors for heart disease and are otherwise healthy, there is a substantial lack of evidence that treating high cholesterol in this group would reduce the number of heart attacks.  Consumer Reports BBD notes that to date, there are no long-term studies that show whether or not doing so reduces the number of heart attacks or other cardiovascular events as the child becomes an adult.  
  • For children with traditional risk factors for heart disease, such as having diabetes or high blood pressure, smoking, those who are overweight or obese (high BMIs), or those with a family history of early-onset heart disease, cholesterol levels may be more important. But lifestyle changes are particularly crucial for this age group, and they include losing weight if needed, increasing exercise and improving a child's diet for at least two years before considering a drug therapy.
  • A 2009 poll by the Consumer Reports National Research Center suggests that consumers think otherwise.  Only half of consumers are correctly informed about evidence supporting prescription medicines used to treat children.  One third (32%) of Americans are under the false impression that drugs to treat conditions in children have always been proven to be safe and effective in children.

Why Some Women Should Think Twice

Today, 22 percent of Americans 45 or older take statins. There are many women within this group and some may have a low risk for cardiovascular disease (CVD). That is an issue because understanding the benefit statins have for these women has not been clear-cut. Some research has been inconclusive due to the use of significantly fewer women than men in trials. And in some cases, trial results were not initially broken down according to gender. Other analyses have found that statin use did not appear to have a beneficial effect on total mortality for women with or without previous CVD. Consumer Reports BBD offers some considerations to help guide decision-making:  

  • Women with elevated LDL cholesterol and no other heart disease risk factors can determine their 10-year risk of heart attack by using a free online tool provided by the National Cholesterol Education Panel: http://hp2010.nhlbihin.net/atpiii/calculator.asp
  • For women with already low or very low risk, as determined by the calculator, there are other actions they can take to reduce the risk of heart attack or heart disease, including stopping smoking, losing weight if needed, increasing exercise, eating a "heart-healthy diet," and taking steps to curb stress.
  • Women's cholesterol might naturally rise after menopause. High levels of HDL, or "good" cholesterol, are beneficial.

For women who require a statin:

  • With all their benefits, statins have downsides that should be considered. Five to 10 percent of users experience mild to severe muscle pain and weakness.   An estimated one percent of people who take statins might develop abnormal liver-function tests.  As with many drugs, we know a lot more about the short-term side effects of statins, like diarrhea and nausea, than the longer-term effects.  That's why statin users should be checked regularly by their doctor.
  • Ask your doctor for the lowest dose possible to achieve your goal of cholesterol reduction.   For most people, a generic statin will be as effective and safe as a branded medicine, and it will cost less.  If you begin to have significant muscle aches after taking a statin, review alternate options with your doctor.
  • The majority of statins can be split in half without any loss of effectiveness.  Good candidates for splitting pills are those statins that cost the same at higher doses, such as Lipitor which costs up to $168 for a monthly supply of 20mg, 40 mg, or 80 mg.  When larger doses cost the same as the smaller dose, you can save money by getting the larger dose and splitting the pills in half.  Consumer Reports BBD recommends talking to your doctor before splitting your statin pills. For a guide to safe and effective pill splitting, go to www.CRBestBuyDrugs.org.

JULY 2010

The material above is intended for legitimate news entities only; it may not be used for advertising or promotional purposes. Consumer Reports® is published by Consumers Union, an expert, independent nonprofit organization whose mission is to work for a fair, just, and safe marketplace for all consumers and to empower consumers to protect themselves.  We accept no advertising and pay for all the products we test. We are not beholden to any commercial interest. Our income is derived from the sale of Consumer Reports,® ConsumerReports.org® and our other publications and information products, services, fees, and noncommercial contributions and grants. Our Ratings and reports are intended solely for the use of our readers. Neither the Ratings nor the reports may be used in advertising or for any other commercial purpose without our permission. Consumers Union will take all steps open to it to prevent commercial use of its materials, its name, or the name of Consumer Reports.®

SOURCE Consumer Reports

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.